Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Free Cash Flow (2016 - 2025)

Vanda Pharmaceuticals' Free Cash Flow history spans 16 years, with the latest figure at -$29.5 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 1353.42% year-over-year to -$29.5 million; the TTM value through Dec 2025 reached -$110.4 million, down 579.76%, while the annual FY2025 figure was -$110.4 million, 579.76% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$29.5 million at Vanda Pharmaceuticals, up from -$31.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $31.8 million in Q1 2023 and bottomed at -$33.6 million in Q1 2025.
  • The 5-year median for Free Cash Flow is $970000.0 (2022), against an average of -$965100.0.
  • The largest annual shift saw Free Cash Flow surged 808.05% in 2021 before it tumbled 1353.42% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $26.5 million in 2021, then plummeted by 65.43% to $9.2 million in 2022, then crashed by 143.54% to -$4.0 million in 2023, then soared by 49.03% to -$2.0 million in 2024, then crashed by 1353.42% to -$29.5 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Free Cash Flow are -$29.5 million (Q4 2025), -$31.8 million (Q3 2025), and -$15.6 million (Q2 2025).